John Hamm
0000-0003-2139-8989
Publication & Citation Trends
Publications
0 total
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial
Cited by 0
Semantic Scholar
A phase 1, first-in-human, multicenter study of ZW251, a novel glypican-3 (GPC3)–targeted antibody-drug conjugate (ADC), in participants with hepatocellular carcinoma (HCC).
Cited by 0
Semantic Scholar
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients With Select Solid Tumors.
Cited by 0
Semantic Scholar
Enhancing lung cancer surgical quality: Insights from a national quality improvement collaborative.
Cited by 0
Semantic Scholar
Design of a first-in-human multicenter open-label study of ZW171, a mesothelin x CD3 targeting bispecific T-cell engager, in participants with advanced solid tumors: ZWI-ZW171-101.
Cited by 0
Semantic Scholar
Strengthening vaccination assessment at a southern oncology center: A quality improvement endeavor.
Cited by 1
Semantic Scholar
Research Topics
Cancer Treatment and Pharmacology
(16)
Lung Cancer Research Studies
(15)
Cancer Immunotherapy and Biomarkers
(13)
Lung Cancer Treatments and Mutations
(13)
Colorectal Cancer Treatments and Studies
(13)
Affiliations
Ontario Institute for Cancer Research
University of Maryland, Baltimore
Novartis (Switzerland)
Google (United States)
The University of Texas MD Anderson Cancer Center